REG - Hikma Pharmaceutical - Total Voting Rights

Hikma PharmaceuticalsAnnouncement

01/03/2024 10:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240301:nRSA2716Fa&default-theme=true

RNS Number : 2716F  Hikma Pharmaceuticals Plc  01 March 2024

 

Hikma Pharmaceuticals PLC

(the Company)

Total Voting Rights and Capital

 

LONDON, 1 March 2024 - In accordance with section 5.6.1 of the UK Financial
Conduct Authority's Disclosure Guidance and Transparency Rules (the 'Rules'),
Hikma Pharmaceuticals PLC notifies the market of the following:

 

As at 29 February 2024, the issued share capital of the Company comprised of
221,885,259 Ordinary Shares of 10 pence each ('Shares') with voting rights.
This figure excludes 12,833,233 Shares held in treasury, which do not have
voting rights.

 

The figure of 221,885,259 may be used by shareholders (and others with
notification obligations) as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the Company under the Rules.

 

 

 

- ENDS -

 

Enquiries

 

 Hikma Pharmaceuticals PLC

 Helen Middlemist           +44 20 7399 2760

 Group Company Secretary

 

 

About Hikma

Hikma helps put better health within reach every day for millions of people
around the world. For more than 45 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,100 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com (http://www.hikma.com)

 

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)

(LEI: 549300BNS685UXH4JI75)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAEDFEFXLEFA